Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Improvement in viral tite.. 63% Improvement Relative Risk Guenezan et al. Povidone-Iodine for COVID-19 RCT EARLY Is early treatment with povidone-iodine beneficial for COVID-19? RCT 24 patients in France Improved viral load with povidone-iodine (not stat. sig., p=0.25) Guenezan et al., JAMA Otolaryngol Head Neck Surg., doi:10.1001/jamaoto.2020.5490 Favors povidone-iodine Favors control
Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial
Guenezan et al., JAMA Otolaryngol Head Neck Surg., doi:10.1001/jamaoto.2020.5490
Guenezan et al., Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With.., JAMA Otolaryngol Head Neck Surg., doi:10.1001/jamaoto.2020.5490
Feb 2021   Source   PDF  
  All Studies   Meta
RCT of PCR+ patients with Ct<=20 with 12 treatment and 12 control patients, concluding that nasopharyngeal decolonization may reduce the carriage of infectious SARS-CoV-2 in adults with mild to moderate COVID-19. All patients but 1 had negative viral titer by day 3 (group not specified). There was no significant difference in viral RNA quantification over time. The mean relative difference in viral titers between baseline and day 1 was 75% [43%-95%] in the intervention group and 32% [10%-65%] in the control group. Thyroid dysfunction occurred in 42% of treated patients, with spontaneous resolution after the end of treatment. Patients in the treatment group were younger.
relative improvement in viral titer reduction between baseline and day 1, 63.2% better, RR 0.37, p = 0.25, treatment 12, control 12.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Guenezan et al., 4 Feb 2021, Randomized Controlled Trial, France, peer-reviewed, 7 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperPovidone-Iod..All
Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19
Jeremy Guenezan, Magali Garcia, Deidre Strasters, Clément Jousselin, Nicolas Lévêque, Denis Frasca, MD Olivier Mimoz
JAMA Otolaryngology–Head & Neck Surgery, doi:10.1001/jamaoto.2020.5490
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is primarily transmitted person-to-person through the aerosolization of droplets containing contaminated nasopharyngeal secretions. 1 Povidone iodine (PI) solutions at concentrations as low as 0.5% rapidly inactivate SARS-CoV-2 in vitro with contact times as short as 15 seconds. 2 We investigated whether nasopharyngeal application of PI could reduce the viral load of patients with nonsevere coronavirus disease 2019 (COVID-19) symptoms.
Conflict of Interest Funding/Support: This project was supported by the University Hospital of Poitiers, France. This study did not benefit from financial support. Role of the Funder/Sponsor: University Hospital of Poitiers, France, had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Data Sharing Statement: See Supplement 2. Additional Contributions: We acknowledge Cynthia Bordage, RN, Bertrand Drugeon, MD, Amélie Mabille, MD, Nicolas Marjanovic, MD, Severine Mousse, MSc, Alexandre Rahoui, MD and Camille Raynaud, MD, who assisted in data collection and patient follow-up, Pierre Dupuis, PharmD, who performed the biochemical tests, and Jeffrey Arsham for editing assistance, all from the University hospital of Poitiers, France. There was no financial compensation for these contributions. OBSERVATION Adolescent Presentation of Nasal Chondromesenchymal Hamartoma: A Case Report and Literature Review Nasal chondromesenchymal hamartoma (NCMH) is a very rare benign tumor of the nasal cavity and paranasal sinuses that usually presents in infancy. These tumors may be expansile and locally destructive. The etiology has remained unclear, but it has been linked in the past to pleuropulmonary blastoma as
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop